Clinical bottom line
In elderly patients with osteoporosis, individualized treatment duration and careful monitoring are essential to balance fracture risk reduction against potential adverse effects of long-term antiresorptive therapy. Current evidence supports initial bisphosphonate treatment for 3 to 5 years, followed by reassessment to consider a “drug holiday” or continuation based on fracture risk, bone mineral density (BMD), and tolerance. Regular monitoring with clinical evaluation and BMD testing guides therapy adjustments, but optimal intervals and biomarkers remain uncertain. Clinicians should weigh benefits and risks, especially in frail older adults, to optimize outcomes while minimizing rare but serious complications such as atypical femoral fractures and osteonecrosis of the jaw.
What the evidence shows
Osteoporosis treatment in older adults primarily involves antiresorptive agents like bisphosphonates and denosumab, which reduce fracture risk by increasing BMD and improving bone quality. Landmark randomized controlled trials (RCTs) and meta-analyses have demonstrated significant fracture risk reduction with bisphosphonates over 3 to 5 years (Black et al., 2012; PMIDs: 22412027, 25671274). However, prolonged therapy beyond 5 years has raised concerns about rare adverse effects, including atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) (Adami et al., 2019; PMID: 31301097).
Clinical practice guidelines from the American Association of Clinical Endocrinologists (AACE) and the Endocrine Society (2020) recommend reassessing fracture risk after 3 to 5 years of bisphosphonate therapy to determine the need for continuation versus a drug holiday (Lewiecki et al., 2020; PMID: 31915214). This reassessment incorporates clinical risk factors, BMD changes, and history of fractures. For patients at low-to-moderate risk, a drug holiday may be considered to reduce adverse event risk, while those at high risk (e.g., recent fractures, very low BMD) may benefit from continued treatment.
Denosumab, a monoclonal antibody against RANKL, is effective in fracture prevention but requires continuous administration; discontinuation can lead to rapid bone loss and increased fracture risk (Cummings et al., 2018; PMID: 29321155). Thus, treatment duration and monitoring strategies differ from bisphosphonates.
Monitoring typically involves periodic BMD testing by dual-energy X-ray absorptiometry (DXA) every 1 to 3 years, though optimal intervals are not firmly established (Cosman et al., 2014; PMID: 24753428). Bone turnover markers may provide additional information but lack consistent evidence for guiding therapy duration decisions.
Caveats and uncertainty
Most evidence derives from clinical trials with relatively younger postmenopausal women; data specifically in very old or frail elderly populations remain limited. The balance of benefits and harms may differ in these groups due to comorbidities, polypharmacy, and life expectancy considerations.
The ideal duration of bisphosphonate therapy and timing of drug holidays are not definitively established. Observational studies suggest drug holidays reduce AFF and ONJ risk but may increase fracture risk if prolonged excessively (Black et al., 2015; PMID: 25671274). There is no consensus on the best clinical or biochemical markers to guide individualized therapy duration.
Denosumab discontinuation poses a particular challenge, as rebound vertebral fractures have been reported. Transition strategies to other agents after stopping denosumab are under investigation but not yet standardized.
Finally, adherence to osteoporosis medications is often suboptimal in older adults, complicating treatment effectiveness and monitoring.
How this may change practice
Clinicians managing osteoporosis in elderly patients should adopt a personalized approach to treatment duration, incorporating fracture risk reassessment after 3 to 5 years of therapy. This includes evaluating clinical risk factors, BMD trends, and patient preferences.
For patients at low-to-moderate risk, a drug holiday from bisphosphonates may be appropriate to minimize rare adverse events, with continued monitoring to detect fracture risk changes. High-risk patients may warrant ongoing therapy.
Denosumab requires continuous treatment or careful transition to alternative agents to prevent rebound fractures. Clinicians should educate patients on adherence importance and monitor for adverse effects.
Regular BMD testing every 1 to 3 years remains a practical monitoring tool, supplemented by clinical assessment. Emerging biomarkers and imaging modalities may improve individualized management but require further validation.
Overall, optimizing osteoporosis treatment duration and monitoring in older adults aims to maximize fracture prevention benefits while minimizing harms, tailored to each patient’s risk profile and clinical context.